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Factors Affecting the Prognosis and Overall 
Survival in Patients with Uterine Papillary 
Serous Carcinoma
IntROduCtIOn
Endometrial cancer remains to be the most common gynaecological 
malignancy worldwide. The disease has been classified into two 
main, clinically and pathologically different, molecular types: Type I is 
much more commonly encountered endometrioid adenocarcinoma 
(80–90%), and Type II comprises non endometrioid subtypes such 
as serous, clear cell, and undifferentiated carcinomas, as well as 
carcinosarcoma/malignant-mixed Müllerian tumour (10-20%), 
according to the ESMO-ESGO-ESTRO Consensus guidelines 
[1]. UPSC is a prototype of Type II EC and represents 5-10% of 
all EC. It is clinically aggressive and responsible for over 50% of 
relapses and deaths in EC patients. These tumours tend to spread 
outside the uterus earlier, they have high recurrence rates, and 
poor prognosis [2-4].
Patterns of spread for UPSC seem to be similar to ovarian cancer. 
Well-known risk factors for tumour spread in EC i.e., primary tumour 
grade, depth of invasion, and lymphovascular space invasion, 
have not been consistently correlated with UPSC spread. Indeed, 
metastatic disease can occur even in the absence of myometrial 
invasion and lymphovascular spread [5]. Lymph node involvement 
was found in up to 36% of UPSC patients with no evidence of 
myometrial invasion [6]. The absence of randomised controlled 
clinical trials for UPSC, due to its rareness, constitutes a significant 
problem. Therefore, the study was conducted with an aim to 
investigate factors affecting the overall survival in UPSC patients.
MAtERIALS And MEthOdS
A retrospective study was performed on all women diagnosed with 
UPSC, treated at the Department of Gynaecologic Oncology, Izmir 
Katip Celebi University, Ataturk Training and Research Hospital, 
Turkey, between January 2006 and October 2015. Institutional 
Ethical Board clearance was obtained before commencement of 
the study. Women with a minimum of 10% component of serous 
carcinoma histologically were included. The cohort was limited to 
the patients who underwent surgical staging which included total 
hysterectomy, bilateral salpingo-oophorectomy, pelvic/para-aortic 
lymph node dissection and omentectomy. The patients without 
surgical treatment because of medical morbidities and those 
who required neoadjuvant chemotherapy were excluded from the 
study. Additionally, patients whose preoperative histopathological 
diagnosis was serous but the final histopathological diagnosis failed 
to meet this criterion were also excluded. Women who underwent 
surgical treatment with at least total hysterectomy and bilateral 
salpingo-oophorectomy were included.
All pathological specimens were evaluated by gynaecologic 
pathologists to confirm the UPSC diagnosis. Socio demographic data, 
systemic diseases, and all data about their disease {histopathology, 
tumour diameter, lymphovascular space involvement, myometrial 
invasion, stage, lymph node metastases (location and count), 
adjuvant therapies, recurrence and survival} were obtained from the 
hospital medical record system.
Tumour stage was retrospectively determined on the basis of surgical 
and pathological findings using the 2009 International Federation of 
Gynecology and Obstetrics (FIGO) staging system for endometrial 
adenocarcinoma [7]. Time elapsed between the diagnosis and 
death or the last follow-up was considered as the overall survival.
The factors that were analysed were the patient’s age, tumour 
diameter, lymphovascular space involvement, myometrial invasion, 
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ABStRACt
Introduction: Uterine Papillary Serous Carcinoma (UPSC) is a 
prototype of Type II Endometrial Cancers (EC) and represents 
5-10% of all EC. It is clinically aggressive and responsible for 
over 50% of relapses and deaths in EC patients.
Aim: To investigate factors affecting the overall survival in 
patients with UPSC.
Materials and Methods: Forty-three women treated for UPSC 
between January 2006 and October 2015 were analysed 
retrospectively. Subjects were included if histology revealed 
a minimum of 10% component of serous carcinoma. Patients 
who required neoadjuvant therapy were excluded. All women 
underwent surgical treatment with at least total hysterectomy 
and bilateral salpingo-oophorectomy. The effect of age, tumour 
size, myometrial invasion, presence of malignant peritoneal 
cytology, lymph node metastasis, presence of the tumour 
outside the uterus and in the upper abdomen on the survival 
were investigated. The Kaplan-Meier method was used for 
survival analysis. Univariate analysis was used to evaluate 
the importance of each parameter and log rank test was used 
for significance. Significant parameters were analysed by 
multivariate Cox regression.
Results: Forty-three patients diagnosed and treated for UPSC 
were analysed. Out of them, 38 (88.4%) underwent surgical 
staging. Relapse and disease progression despite therapy was 
observed in 9 (20.9%) cases. The overall survival was estimated 
to be 46.5%.
Conclusion: The present study demonstrated that myometrial 
invasion, lymphovascular space involvement, and presence of 
a tumour in the upper abdomen were statistically significant 
parameters affecting the overall survival in UPSC patients.
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Parameters number Percent
histology
Endometrioid 10 23.3
Serous 18 41.9
Indifferent 1 2.3
Mixed 9 20.9
Unknown 5 11.6
Smear
Absent 16 37.2
Benign 20 46.5
AG-NOS 1 2.3
Adenocarcinoma 6 14.0
Systemic disease
Diabetes 16 37.2
Hypertension 21 48.8
metachronous 
malignancy
Ovary 4 9.3
Colon 1 2.3
Breast 3 7
Other 3 7
Final 
histopathology
Serous 25 58.1
Mixed 
(Serous+endometrioid)
18 41.8
Surgical 
procedure
Total abdominal 
hysterectomy+bilaterally 
salphingo-
oophorectomy
43 100
Pelvic lymph node 
dissection
34 79.1
Para-aortic lymph node 
dissection
23 53.5
Omentectomy 28 65.1
FIGO stage
IA 14 32.6
IB 5 11.6
II 1 2.3
IIIA 6 14
IIIB 1 2.3
IIIC1 1 2.3
IIIC2 3 7.0
IVA 0 0
IVB 12 27.9
adjuvant 
treatment
None 7 16.3
Radiotherapy 12 27.9
Chemotherapy 11 25.6
Chemotherapy 
combined with 
radiotherapy
13 30.2
Site of 
extrauterine 
disease
Ovary 13 30.2
Pelvic lymph node 10 23.2
Para-aortic lymph node 6 14
Omentum 12 27.9
Carcinomatosis 10 23.2
Site of recurrence 
Abdomen 4 44.4
Lymph node 3 33.3
Pulmonary 1 11.1
Multiple 1 11.1
[table/Fig-1]: Patient characteristics.
Of the total 43 patients, 9 (20.9%) developed disease progression and 
14 (32.6%) had a relapse. Mean relapse time was 9.9 months (range: 
5-17months). Two of the patients with recurrences are still alive. At the 
time of follow-up, 20 (46.5%) patients had survived, 21 patients had 
succumbed to the disease, one patient had succumbed to stroke, 
and one patient died due to early postoperative complications.
the existence of malignant cells in the peritoneal cavity, lymphatic 
metastasis, stage, and presence of tumour in the upper abdomen 
on the overall survival.
StAtIStICAL AnALySIS
Descriptive statistics were used to report patient demographics 
for all patients. Associations between categorical variables was 
analysed using Pearson’s chi-square and Fisher’s exact test. Survival 
curves by stages were generated using the Kaplan-Meier method. 
Univariate analysis was used to evaluate the importance of each 
parameter and log rank test was used for significance. Multivariate 
analysis was performed to identify independent predictors of survival 
using a Cox proportional hazards model and backwards stepwise 
selection. The SPSS statistical package version 22.0 was used to 
perform all statistical analyses (SPSS Inc., Chicago, IL, USA). The 
level of significance was two tailed, p<0.05.
RESuLtS
A total of 737 patients with the diagnosis of EC were treated at 
the Department of Gynaecologic Oncology, between January 2006 
and October 2015. The initial medical record search identified 57 
patients with UPSC during that period. Despite detecting UPSC in 
the preoperative biopsy specimens of 10 patients, none of them 
had UPSC in the operative specimens. Two patients who received 
no surgical treatment and two patients who were operated on after 
neoadjuvant chemotherapy were excluded from the study cohort. 
As a result, 43 patients with UPSC, who met all the necessary 
criteria were analysed.
UPSC represented 6.38% of our entire EC cohort. Median age 
at diagnosis was 65 years (range, 49-82 years). All patients were 
postmenopausal.
All patients underwent total hysterectomy and bilateral salpingo-
oophorectomy, 38 (88.4%) patients were subjected to surgical 
staging. Omentectomy was performed in 28 patients, while 34 
underwent pelvic lymph node dissection and 23 also had para-aortic 
lymph node dissection. Seven patients underwent more advanced 
cytoreductive surgery. Mean number of the removed lymph nodes 
was 29.91±20.42 (range: 2-86), 23.71±14.40 in the pelvic area 
(range: 1-58) and 8.61±7.57 in the para-aortic area (range: 1-28).
In the present study cohort, 26 of the 43 (60.5%) patients had 
serous tumour as the real initial diagnosis in their preoperative 
biopsy specimens.
In 19 (44.2%) cases the tumour infiltrated <50% of the myometrial 
thickness. Again in 19 (44.2%) cases the infiltration was found 
to be >50% (deep infiltration) and in 5 (11.6%) cases the tumour 
was limited to the endometrium. Extrauterine disease was 
observed in one of the five patients without myometrial invasion. 
Extrauterine disease was found in 10 of 24 (41.7%) patients who 
had no deep myometrial invasion: lymph node metastasis (5), 
adnexal metastases (5), omental implants (7), and malignant cells 
in abdominal cytology (6). Lymphovascular space invasion was 
identified in 20 (46.5%) patients.
There were 19 (44.2%) patients with Stage I, 1 (2.3%) with Stage 
II, 11 (25.6%) with Stage III, and 12 (27.9%) with Stage IV disease. 
Patient characteristics are presented in [Table/Fig-1]. According 
to the postoperative histopathological examinations, 25 (58.1%) 
patients had pure UPSC and 18 (41.8%) had mixed (serous and 
endometrioid) types. Overall, four mixed carcinomas were well-
differentiated, 10 were moderately well-differentiated, and four were 
poorly differentiated.
Adjuvant treatment was administered to 83.7% of the patients, 
chemo-radiotherapy to 30.2%, only radiotherapy to 27.9% and 
just chemotherapy to 25.6%. A total of 16.3% did not receive any 
adjuvant therapy.  The chemotherapy regimen was carboplatin and 
paclitaxel every three weeks.
www.jcdr.net Incim Bezircioglu et al., Prognosis and Survival in Uterine Papillary Serous Carcinoma
Journal of Clinical and Diagnostic Research. 2018 May, Vol-12(5): QC01-QC05 3
Median follow-up time for all patients was 20.02±17.3 months (range: 
0-63.67 months), and for the survivors it was 27.36±18.77 months 
(range: 5.43-63.67 months). Median survival was 25.50±12.60 
months (95% CI=0.799-50.201). Overall survival curve considering 
stages of the disease is shown in [Table/Fig-2]. 
and should therefore be treated as high-grade tumours [8,9]. A 
retrospective study by Fader AN et al., suggests that patients with 
a UPSC component within the tumour specimens carry a significant 
risk for recurrence and had lower survival rates [10]. Lawrenson K 
et al., suggested that molecular profiles of mixed type endometrial 
adenocarcinoma closely resembled the molecular profiles of 
pure UPSC, and even mixed cases, which are predominantly 
endometrioid adenocarcinomas, will have clinical courses like pure 
UPSC tumours [11]. Thus, in the present study pure and mixed 
cases of UPSC were considered together.
UPSC represents <10% of all EC [2]. In the present study it was 
found that UPSC constituted just 6.38% of our entire EC cohort. 
UPSC is generally diagnosed in more advanced age as compared 
to pure EC. Many authors reported mean age of UPSC subjects to 
be 62-70 years [12-16]. Similarly, median age of our patients was 
65 years. The age over 65 years is reported to be an independent 
bad criterion for recurrence and poor survival in UPSC cases [17]. It 
was also found that advanced age (>65) years acts as a significant 
risk factor for poor prognosis.
UPSC frequently presents with extrauterine disease at diagnosis. 
Nearly half of UPSC patients present with extrauterine disease 
and 46% of those patients with UPSC are found to be Stage II-IV 
as compared to 21% for all EC. Numerous authors reported early 
stage/limited to the uterine corpus cases in UPSC tumours to be 
in the range of 31-54% [12,13,17-19]. Moreover, even in Stage I 
non invasive UPSC, prior studies reported up to 50% risk of occult 
extrauterine disease even when the disease seems to be confined to 
the endometrium [20]. In their retrospectively evaluated series, Ball A 
et al., showed that 53.1% of clinically early 64 UPSC patients (Stage I) 
Variables p Or
95% cI for Or
lower upper
Deep myometrial 
invasion
0.073 4.192 0.877 20.032
lymphovascular space 
invasion
0.015 0.130 0.025 0.671
lymph node 
involvement
0.005 7.191 1.808 28.608
Presence of the tumour 
on upper abdomen
0.040 5.181 1.082 24.805
[table/Fig-5]: The results of Cox regression analysis made by backward stepwise 
linear regression method for the factors considered to have an effect on overall 
survival.
Omnibus test chi-square, p<0.05=significant
Variables p Or
95% cI for Or
lower upper
age (≥65) years 0.913 0.901 0.139 5.839
tumour size 
(≥2 mm) 0.306 0.244 0.016 3.624
myometrial 
invasion (≥50%) 0.032 8.659 1.203 62.315
lymphovascular 
space invasion
0.155 0.219 0.027 1.776
malignant 
cytology
0.710 0.533 0.019 14.736
lymph node 
involvement
0.026 17.786 1.410 224.325
Presence of the 
tumour on upper 
abdomen
0.140 9.355 0.480 182.208
adjuvant 
treatment
0.382 0.247 0.011 5.702
chemotherapy 0.671 0.517 0.025 10.848
Omentectomy 0.296 0.251 0.019 3.355
[table/Fig-4]: Cox-regression analysis for the prognostic factors considered to 
have an effect on overall survival.
Omnibus test chi-square, p<0.05=significant
Variables
total
mortality at 
 follow-up p-value
n % n %
age (≥65) years 22 51.2 15 68.18 0.048
tumour size (≥2 mm) 29 67.4 14 48.3 1.000
myometrial invasion 
(≥50%) 19 44.2 11 57.9 0.606
lymphovascular space 
invasion
20 46.5 12 60 0.425
malignant cytology 14 32.5 9 64.3 0.330
Presence of the tumour 
on upper abdomen
12 27.9 8 66.7 0.281
Omentectomy 28 65.1 15 53.6 0.988
lymph node dissection 34 79.1 17 50 0.467
lymph node 
involvement 
11 25.5 9 81.8 0.015
adjuvant treatment 36 83.7 18 50 0.420
chemotherapy 23 53.5 13 56.5 0.669
[table/Fig-3]: The distribution of the prognostic variables for survival.
Pearson chi-square, Fisher’s exact test, p<0.05=significant
As shown in [Table/Fig-3], only advanced age and lymph node 
metastases were detected as statistically significant prognostic risk 
factors for survival.
According to the Cox regression analysis for factors considered 
to have an effect on the overall survival, myometrial invasion and 
lymph node involvement have statistically significant effects on the 
overall survival (p<0.05). Results of the Cox regression analysis are 
represented in [Table/Fig-4]. These factors were re-evaluated by the 
backward stepwise Linear Regression (LR) method. Significant results 
are shown in [Table/Fig-5]. Cox regression analysis made by backward 
stepwise LR method revealed lymphovascular space invasion, lymph 
node involvement, and presence of the tumour in the upper abdomen 
to be statistically significant risk factors for the overall survival.
dISCuSSIOn
The present study was a single-institution retrospective analysis of 
all patients with pure and mixed UPSC managed for about a 10-
year period. Mixed tumours with a serous component, even <10%, 
have worse prognosis than pure endometrioid adenocarcinomas 
[table/Fig-2]: Kaplan-Meier curve of overall survival by stages.
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were in fact Stage I, but 46.9% had to be upstaged after surgical 
staging [13].
In the present study, stage was assigned retrospectively and 
incompletely staged patients as well as the unevaluated sites were 
considered to be negative. Thus, the findings of the present study 
cannot determine the percentage of patients who should have been 
considered in the upper stages. Extrauterine disease was found in 
53.5% of the present study cohort. Moreover, extrauterine disease 
was established in one of the five patients without myometrial 
invasion.
Recommendations for the surgical and adjuvant treatment for UPSC 
patients differ from those for pure endometrioid type endometrial 
carcinoma cases. Known surgical-pathologic risk factors for 
endometrial type endometrial carcinoma, including deep myometrial 
invasion, lymphovascular invasion, and tumour size, were not 
significantly associated with extrauterine spread in UPSC [6,10,16]. 
Due to higher incidence of occult extrauterine involvement, surgical 
staging including hysterectomy, bilateral salpingo-oophorectomy, 
peritoneal washings, pelvic and para-aortic lymphadenectomy and 
omentectomy were recommended widely, even in patients classified 
clinically as very early stage. Basic recommendations include 
surgical staging in clinically early-stage patients to determine occult 
extrauterine sites of the disease and designate adjuvant therapy, as 
well as debulking surgery in advanced stages, similarly to ovarian 
cancer. Unfortunately, preoperatively performed endometrial 
biopsies have low sensitivity rates for UPSC. Consequently, the rate 
of pre operatively false diagnosis as endometrioid type carcinoma 
is high, and 25-50% of UPSC patients are diagnosed on post 
operatively reported final pathology [12,21]. Therefore, great number 
of these cases undergo inadequate surgical treatment. In the 
present study cohort, 41.9% had serous tumour as the actual initial 
diagnosis and 20.9% had mixed endometrial carcinomas (serous 
and endometrioid), and 37.2% of the patients were diagnosed with 
UPSC on final pathology post operatively.
In the present study, surgical staging was performed including 
lymphatic dissection in 34 (79%) and omentectomy in 28 (65.1%) 
of 43 patients. In similar retrospective USPC studies, adequate 
surgical staging rates were reported to be 60-81% [12,13,17,18].
UPSC has a higher tendency to spread to pelvic/para-aortic 
lymph nodes as compared to endometrioid carcinoma. In similar 
retrospective UPSC studies, lymph node metastasis rates were 
reported to range from 21.4% to 43.8% [11,14,21,22]. Goff BA et 
al., reported that 42% of all patients (21/50) undergoing surgery had 
lymph node metastases, and of these, 10 had para-aortic nodal 
metastases, with or without pelvic nodal metastases. This translates 
into a 20% overall risk of para-aortic nodal metastases [6]. Mattes 
MD et al., reported that 29% of all patients had lymph node and 
54.3% of them had just pelvic metastases. The 43.7% of cases 
with para-aortic metastases had also positive pelvic nodes [15]. 
However, in the present study it was found that 25.5% of cases were 
of lymph metastases; the rate of positive para-aortic nodes was 
13.95%. Interestingly, 2.3% had metastases only in the para-aortic 
region. Removal of over 10 pelvic lymph nodes was considered to 
be adequate in a study by Mariani A et al., [23]. Mean number of 
extirpated lymph nodes in the present study was 29 and this was 
considered to be sufficient to detect occult lymphatic involvements.
Peled Y et al., investigated the effect of omentectomy on survival 
in a study with 52 cases. They performed omentectomy in 30 
(58%) patients and found omental metastasis in 10%. A total of 
77% of the cases received adjuvant chemotherapy. These authors 
considered that omitting omentectomy in cases with a visually 
normal appearing omentum has no effect on disease-free survival, 
time to recurrence, as well as the overall survival, and concluded that 
possible undetected micro-metastases in the left omentum will be 
influenced by adjuvant chemotherapy [21]. In the present study 12 
patients, out of 28 with omentectomy, were found to have omental 
involvement; however, no effect of this procedure was observed on 
the prognosis of the disease.
The risk for recurrence of UPSC is high and increases with stage. 
Disease recurrence is common even in patients with non invasive 
serous carcinomas limited to the endometrium. Although, most 
patients with UPSC receive post operative adjuvant therapy, over 
a third of the patients (44%) develop recurrence. Most recurrences 
occur within the first three years of diagnosis [14,21].
UPSC tends to recur at distant sites. Huang CY et al., reported that 
62.5% of patients with disease recurrence had tumours outside the 
pelvic cavity [12]. Similarly, Gadducci A et al., found that recurrent 
disease involved the peritoneum or distant sites in 66.7% of their 
UPSC patients [24]. Pol F et al., also found that 32/62 patients 
experienced a recurrence, with 81% having recurrences in their upper 
abdomen and/or other distant metastases [18]. In the present cohort, 
14 patients (32.6%) developed relapse and all of these recurrences 
were in their upper abdomen and/or other distant sites. We found 
no solitary pelvic recurrence apart from patients with multiple 
recurrences.
Considering the tendency of UPSC for distant recurrence, adjuvant 
treatment should include both, systemic and local therapy. 
Chemotherapy significantly improves relapse-free survival and the 
overall survival in all stages [17]. Chemo-radiotherapy should be 
performed as adjuvant treatment for all patients with incomplete 
staging and also for all patients in advanced stages. Fader AN et al., 
investigated the role of chemotherapy in Stage I UPSC and showed 
that early-stage patients treated with adjuvant chemotherapy 
experienced significantly improved survival as compared to patients 
who received no adjuvant therapy or just radiotherapy [10].
Surgical-pathologic risk factors for endometrial type endometrial 
carcinoma, including deep myometrial invasion and tumour size, were 
not confirmed to be significantly associated with recurrence or survival 
in UPSC by several authors [6,10,16]. In the pre treatment variables, 
only age was prognostic for survival in the present cohort. Additionally, 
deep myometrial invasion and lymphovascular space invasion as 
surgical-pathologic risk factors affected the overall survival.
Rauh-Hain JA et al., analysed factors which influenced mortality 
in 13752 patients recorded in the National Cancer Database, and 
stated that age and advanced stage were the most important 
prognostic parameters. Their analysis also indicated that omitting 
definitive surgery as well as proper lymph node dissection is 
related with poor survival. They also found that chemo-radiation 
was associated with improved survival, but not radiotherapy or 
chemotherapy alone [17].
Lee LJ et al., demonstrated the importance of treatment-related 
factors, including optimal cytoreductive surgery as well as the use 
of adjuvant therapy, to decrease recurrence and improve survival 
in patients with advanced stage UPSC. Optimal cytoreduction is 
one of the most important determinants of survival in patients with 
advanced stage UPSC, just like epithelial ovarian cancers [16]. 
Similarly, Ball A et al., showed in a multivariate analysis that early 
stage, adjuvant chemotherapy and complete surgical staging are 
independent variables which prolong disease-free survival [13].
LIMItAtIOn
The present study had a small sample size and comprised different 
stage patients. Surgical and adjuvant management of the disease 
may change depending on disease stage. Also, guidelines for 
optimal treatment changed over time. Due to relatively small sample 
size, it was not possible to evaluate the effectiveness of the stage 
and this is probably also the reason why the variables related to the 
therapy did not show significant effect on the prognosis. Another 
limitation of this study is its retrospective nature, as well as the fact 
that data about the cause of death of our patients are obtained from 
official health registrations. 
www.jcdr.net Incim Bezircioglu et al., Prognosis and Survival in Uterine Papillary Serous Carcinoma
Journal of Clinical and Diagnostic Research. 2018 May, Vol-12(5): QC01-QC05 5
PartIcularS OF cOntrIButOrS:
1. Associate Professor, Department of Obstetrics and Gynaecology, Izmir Economy University Hospital, Izmir, Turkey.
2. Department of Obstetrics and Gynaecology, Izmir Economy University Hospital, Izmir, Turkey.
3. Assistant Professor, Department of Obstetrics and Gynaecology, Pamukkale University Hospital, Denizli, Turkey.
name, aDDreSS, e-maIl ID OF the cOrreSPOnDInG authOr:
Dr. Incim Bezircioglu,
Yenice Distinct, Mezbaha Street, 48/2, Urla-35430, Izmir, Turkey.
E-mail: drincimbezircioglu@yahoo.com
FInancIal Or Other cOmPetInG IntereStS: None.
Date of Submission: mar 19, 2017
Date of Peer Review: Jun 04, 2017
Date of Acceptance: Jan 29, 2018
Date of Publishing: may 01, 2018
COnCLuSIOn
There is an obvious need for prospective studies in UPSC patients 
with larger sample size and with special emphasis on lymphovascular 
space invasion, lymph node involvement, and presence of the 
tumour in the upper abdomen, as well as guidelines which may 
recommend more radical surgeries for the first operation.
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